New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Radiopharm Theranostics Limited - Sponsored ADR (RADX) Return on invested capital

Alert me on Return on invested capital

Return on invested capital, annual

Embed this chart

Annual newest first

Period Return on invested capital Change (points)
FY2026 −195.2% (21.70)
FY2025 −173.5% 162.68
FY2024 −336.1% —

Return on invested capital against peers

Company Return on invested capital
BIVI BioVie Inc. compare 0.00%
HIND Vyome Holdings, Inc. compare 0.00%
AEON AEON Biopharma, Inc. compare 0.00%
LSTA Lisata Therapeutics, Inc. compare 0.00%
BCDA BioCardia, Inc. compare 0.00%
PASG Passage Bio, Inc. compare 0.00%
LEXX Lexaria Bioscience Corp. compare −662.6%
RADX Radiopharm Theranostics Limited - Sponsored ADR —
PBM Psyence Biomedical Ltd. compare —
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 0.06%

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on RADX